APO Research
Talk to an analyst

APO RESEARCH · REPORT

Idiopathic Pulmonary Fibrosis Disease Treatment

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Idiopathic Pulmonary Fibrosis Disease Treatment Industry Growth and Trends Forecast to 2032

2 January 2026101 pages

Choose your research edition.

Industry ResearchIdiopathic Pulmonary Fibrosis Disease Treatment Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Idiopathic Pulmonary Fibrosis Disease Treatment Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Idiopathic Pulmonary Fibrosis Disease Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Idiopathic Pulmonary Fibrosis Disease Treatment Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Idiopathic Pulmonary Fibrosis Disease Treatment Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

According to APO Research, the global Idiopathic Pulmonary Fibrosis Disease Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Idiopathic Pulmonary Fibrosis Disease Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Idiopathic Pulmonary Fibrosis Disease Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Idiopathic Pulmonary Fibrosis Disease Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the Idiopathic Pulmonary Fibrosis Disease Treatment market include Blade Therapeutics, Bristol Myers Squibb, InterMune, Inc., Vicore Pharma, ArkBio, Boehringer Ingelheim, Regend Therapeutics (Cayman) Ltd., Merck and Co., Inc. and SHIONOGI & CO., Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Idiopathic Pulmonary Fibrosis Disease Treatment market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Idiopathic Pulmonary Fibrosis Disease Treatment market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Idiopathic Pulmonary Fibrosis Disease Treatment market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Idiopathic Pulmonary Fibrosis Disease Treatment.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Idiopathic Pulmonary Fibrosis Disease Treatment market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Idiopathic Pulmonary Fibrosis Disease Treatment Market by Company

Blade Therapeutics

Bristol Myers Squibb

InterMune, Inc.

Vicore Pharma

ArkBio

Boehringer Ingelheim

Regend Therapeutics (Cayman) Ltd.

Merck and Co., Inc.

SHIONOGI & CO., Ltd.

Insilico Medicine

Indaco

Zelgen

Heilongjiang Zbd Pharmaceutical

Idiopathic Pulmonary Fibrosis Disease Treatment Segment by Type

Pirfenidone

Nintedanib

Other

Idiopathic Pulmonary Fibrosis Disease Treatment Segment by Application

Hospital

Graduate School

Others

Idiopathic Pulmonary Fibrosis Disease Treatment Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Idiopathic Pulmonary Fibrosis Disease Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Idiopathic Pulmonary Fibrosis Disease Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Idiopathic Pulmonary Fibrosis Disease Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Idiopathic Pulmonary Fibrosis Disease Treatment companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Share by Region (2021-2026) Table 4. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Share by Region (2027-2032) Table 6. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Share by Type (2021-2026) Table 9. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Share Forecasted by Type (2027-2032) Table 11. North America Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Share by Application (2021-2026) Table 24. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Share Forecasted by Application (2027-2032) Table 26. North America Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Idiopathic Pulmonary Fibrosis Disease Treatment Industry Trends Table 37. Idiopathic Pulmonary Fibrosis Disease Treatment Industry Drivers Table 38. Idiopathic Pulmonary Fibrosis Disease Treatment Industry Opportunities and Challenges Table 39. Idiopathic Pulmonary Fibrosis Disease Treatment Industry Restraints Table 40. Global Idiopathic Pulmonary Fibrosis Disease Treatment Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Idiopathic Pulmonary Fibrosis Disease Treatment Revenue Market Share by Company (2021-2026) Table 42. Global Idiopathic Pulmonary Fibrosis Disease Treatment Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Idiopathic Pulmonary Fibrosis Disease Treatment Key Company Headquarters & Area Served Table 44. Global Idiopathic Pulmonary Fibrosis Disease Treatment Company, Product Type & Application Table 45. Global Idiopathic Pulmonary Fibrosis Disease Treatment Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Idiopathic Pulmonary Fibrosis Disease Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Blade Therapeutics Company Information Table 49. Blade Therapeutics Business Overview Table 50. Blade Therapeutics Idiopathic Pulmonary Fibrosis Disease Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Blade Therapeutics Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio Table 52. Blade Therapeutics Recent Development Table 53. Bristol Myers Squibb Company Information Table 54. Bristol Myers Squibb Business Overview Table 55. Bristol Myers Squibb Idiopathic Pulmonary Fibrosis Disease Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Bristol Myers Squibb Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio Table 57. Bristol Myers Squibb Recent Development Table 58. InterMune, Inc. Company Information Table 59. InterMune, Inc. Business Overview Table 60. InterMune, Inc. Idiopathic Pulmonary Fibrosis Disease Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. InterMune, Inc. Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio Table 62. InterMune, Inc. Recent Development Table 63. Vicore Pharma Company Information Table 64. Vicore Pharma Business Overview Table 65. Vicore Pharma Idiopathic Pulmonary Fibrosis Disease Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. Vicore Pharma Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio Table 67. Vicore Pharma Recent Development Table 68. ArkBio Company Information Table 69. ArkBio Business Overview Table 70. ArkBio Idiopathic Pulmonary Fibrosis Disease Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. ArkBio Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio Table 72. ArkBio Recent Development Table 73. Boehringer Ingelheim Company Information Table 74. Boehringer Ingelheim Business Overview Table 75. Boehringer Ingelheim Idiopathic Pulmonary Fibrosis Disease Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. Boehringer Ingelheim Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio Table 77. Boehringer Ingelheim Recent Development Table 78. Regend Therapeutics (Cayman) Ltd. Company Information Table 79. Regend Therapeutics (Cayman) Ltd. Business Overview Table 80. Regend Therapeutics (Cayman) Ltd. Idiopathic Pulmonary Fibrosis Disease Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. Regend Therapeutics (Cayman) Ltd. Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio Table 82. Regend Therapeutics (Cayman) Ltd. Recent Development Table 83. Merck and Co., Inc. Company Information Table 84. Merck and Co., Inc. Business Overview Table 85. Merck and Co., Inc. Idiopathic Pulmonary Fibrosis Disease Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. Merck and Co., Inc. Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio Table 87. Merck and Co., Inc. Recent Development Table 88. SHIONOGI & CO., Ltd. Company Information Table 89. SHIONOGI & CO., Ltd. Business Overview Table 90. SHIONOGI & CO., Ltd. Idiopathic Pulmonary Fibrosis Disease Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. SHIONOGI & CO., Ltd. Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio Table 92. SHIONOGI & CO., Ltd. Recent Development Table 93. Insilico Medicine Company Information Table 94. Insilico Medicine Business Overview Table 95. Insilico Medicine Idiopathic Pulmonary Fibrosis Disease Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. Insilico Medicine Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio Table 97. Insilico Medicine Recent Development Table 98. Indaco Company Information Table 99. Indaco Business Overview Table 100. Indaco Idiopathic Pulmonary Fibrosis Disease Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 101. Indaco Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio Table 102. Indaco Recent Development Table 103. Zelgen Company Information Table 104. Zelgen Business Overview Table 105. Zelgen Idiopathic Pulmonary Fibrosis Disease Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 106. Zelgen Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio Table 107. Zelgen Recent Development Table 108. Heilongjiang Zbd Pharmaceutical Company Information Table 109. Heilongjiang Zbd Pharmaceutical Business Overview Table 110. Heilongjiang Zbd Pharmaceutical Idiopathic Pulmonary Fibrosis Disease Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 111. Heilongjiang Zbd Pharmaceutical Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio Table 112. Heilongjiang Zbd Pharmaceutical Recent Development Table 113. North America Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 114. North America Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Country (2021-2026) & (US$ Million) Table 115. North America Idiopathic Pulmonary Fibrosis Disease Treatment Market Share by Country (2021-2026) Table 116. North America Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 117. North America Idiopathic Pulmonary Fibrosis Disease Treatment Market Share Forecast by Country (2027-2032) Table 118. Europe Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 119. Europe Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Country (2021-2026) & (US$ Million) Table 120. Europe Idiopathic Pulmonary Fibrosis Disease Treatment Market Share by Country (2021-2026) Table 121. Europe Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 122. Europe Idiopathic Pulmonary Fibrosis Disease Treatment Market Share Forecast by Country (2027-2032) Table 123. Asia-Pacific Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 124. Asia-Pacific Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Country (2021-2026) & (US$ Million) Table 125. Asia-Pacific Idiopathic Pulmonary Fibrosis Disease Treatment Market Share by Country (2021-2026) Table 126. Asia-Pacific Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 127. Asia-Pacific Idiopathic Pulmonary Fibrosis Disease Treatment Market Share Forecast by Country (2027-2032) Table 128. Latin America Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 129. Latin America Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Country (2021-2026) & (US$ Million) Table 130. Latin America Idiopathic Pulmonary Fibrosis Disease Treatment Market Share by Country (2021-2026) Table 131. Latin America Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 132. Latin America Idiopathic Pulmonary Fibrosis Disease Treatment Market Share Forecast by Country (2027-2032) Table 133. Middle East & Africa Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 134. Middle East & Africa Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Country (2021-2026) & (US$ Million) Table 135. Middle East & Africa Idiopathic Pulmonary Fibrosis Disease Treatment Market Share by Country (2021-2026) Table 136. Middle East & Africa Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 137. Middle East & Africa Idiopathic Pulmonary Fibrosis Disease Treatment Market Share Forecast by Country (2027-2032) Table 138. Research Programs/Design for This Report Table 139. Authors List of This Report Table 140. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Idiopathic Pulmonary Fibrosis Disease Treatment Product Image Figure 3. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size (2021-2032) & (US$ Million) Figure 5. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Share by Region: 2025 VS 2032 Figure 6. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Share by Region (2021-2032) Figure 7. North America Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Pirfenidone Image Figure 13. Global Pirfenidone Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. Nintedanib Image Figure 15. Global Nintedanib Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Other Image Figure 17. Global Other Market Size YoY Growth (2021-2032) & (US$ Million) Figure 18. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Overview by Type (2021-2032) & (US$ Million) Figure 19. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Share by Type 2025 VS 2032 Figure 20. North America Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Share by Type (2021-2032) Figure 21. Europe Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Share by Type (2021-2032) Figure 22. Asia-Pacific Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Share by Type (2021-2032) Figure 23. Latin America Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Share by Type (2021-2032) Figure 24. Middle East and Africa Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Share by Type (2021-2032) Figure 25. Hospital Image Figure 26. Global Hospital Market Size YoY Growth (2021-2032) & (US$ Million) Figure 27. Graduate School Image Figure 28. Global Graduate School Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. Others Image Figure 30. Global Others Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Overview by Application (2021-2032) & (US$ Million) Figure 32. Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Share by Application 2025 VS 2032 Figure 33. North America Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Share by Application (2021-2032) Figure 34. Europe Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Share by Application (2021-2032) Figure 35. Asia-Pacific Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Share by Application (2021-2032) Figure 36. Latin America Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Share by Application (2021-2032) Figure 37. Middle East and Africa Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Share by Application (2021-2032) Figure 38. Global Top 5 and 10 Idiopathic Pulmonary Fibrosis Disease Treatment Players Market Share by Revenue in 2025 Figure 39. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 40. North America Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 41. North America Idiopathic Pulmonary Fibrosis Disease Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 42. North America Idiopathic Pulmonary Fibrosis Disease Treatment Market Share by Country (2021-2032) Figure 43. Europe Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. Europe Idiopathic Pulmonary Fibrosis Disease Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Idiopathic Pulmonary Fibrosis Disease Treatment Market Share by Country (2021-2032) Figure 46. Asia-Pacific Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 47. Asia-Pacific Idiopathic Pulmonary Fibrosis Disease Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 48. Asia-Pacific Idiopathic Pulmonary Fibrosis Disease Treatment Market Share by Country (2021-2032) Figure 49. Latin America Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Latin America Idiopathic Pulmonary Fibrosis Disease Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Latin America Idiopathic Pulmonary Fibrosis Disease Treatment Market Share by Country (2021-2032) Figure 52. Middle East & Africa Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 53. Middle East & Africa Idiopathic Pulmonary Fibrosis Disease Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 54. Middle East & Africa Idiopathic Pulmonary Fibrosis Disease Treatment Market Share by Country (2021-2032) Figure 55. Years Considered Figure 56. Research Process Figure 57. Key Executives Interviewed

Scope & coverage.

Types
  • Pirfenidone
  • Nintedanib
  • Other
Applications
  • Hospital
  • Graduate School
  • Others
Companies covered
  • Blade Therapeutics
  • Bristol Myers Squibb
  • InterMune, Inc.
  • Vicore Pharma
  • ArkBio
  • Boehringer Ingelheim
  • Regend Therapeutics (Cayman) Ltd.
  • Merck and Co., Inc.
  • SHIONOGI & CO., Ltd.
  • Insilico Medicine
  • Indaco
  • Zelgen
  • Heilongjiang Zbd Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Region (2021-2032)
  5. 1.4.1 Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Region (2021-2026)
  6. 1.4.2 Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Region (2027-2032)
  7. 1.5 Key Regions Idiopathic Pulmonary Fibrosis Disease Treatment Market Size (2021-2032)
  8. 1.5.1 North America Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Growth Rate (2021-2032)
2 Idiopathic Pulmonary Fibrosis Disease Treatment Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 Pirfenidone
  3. 2.1.2 Nintedanib
  4. 2.1.3 Other
  5. 2.2 Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Type
  6. 2.2.1 Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Overview by Type (2021-2032)
  7. 2.2.2 Global Idiopathic Pulmonary Fibrosis Disease Treatment Historic Market Size Review by Type (2021-2026)
  8. 2.2.3 Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Forecasted by Type (2027-2032)
  9. 2.3 Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Regions
  10. 2.3.1 North America Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Breakdown by Type (2021-2026)
  11. 2.3.2 Europe Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Breakdown by Type (2021-2026)
  12. 2.3.3 Asia-Pacific Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Breakdown by Type (2021-2026)
  13. 2.3.4 South America Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Breakdown by Type (2021-2026)
  14. 2.3.5 Middle East and Africa Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Breakdown by Type (2021-2026)
3 Idiopathic Pulmonary Fibrosis Disease Treatment Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Hospital
  3. 3.1.2 Graduate School
  4. 3.1.3 Others
  5. 3.2 Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Application
  6. 3.2.1 Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Overview by Application (2021-2032)
  7. 3.2.2 Global Idiopathic Pulmonary Fibrosis Disease Treatment Historic Market Size Review by Application (2021-2026)
  8. 3.2.3 Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Forecasted by Application (2027-2032)
  9. 3.3 Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Regions
  10. 3.3.1 North America Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Breakdown by Application (2021-2026)
  11. 3.3.2 Europe Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Breakdown by Application (2021-2026)
  12. 3.3.3 Asia-Pacific Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Breakdown by Application (2021-2026)
  13. 3.3.4 South America Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Breakdown by Application (2021-2026)
  14. 3.3.5 Middle East and Africa Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Idiopathic Pulmonary Fibrosis Disease Treatment Industry Trends
  2. 4.2 Idiopathic Pulmonary Fibrosis Disease Treatment Industry Drivers
  3. 4.3 Idiopathic Pulmonary Fibrosis Disease Treatment Industry Opportunities and Challenges
  4. 4.4 Idiopathic Pulmonary Fibrosis Disease Treatment Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Idiopathic Pulmonary Fibrosis Disease Treatment Revenue (2021-2026)
  2. 5.2 Global Idiopathic Pulmonary Fibrosis Disease Treatment Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Idiopathic Pulmonary Fibrosis Disease Treatment Key Company Headquarters & Area Served
  4. 5.4 Global Idiopathic Pulmonary Fibrosis Disease Treatment Company, Product Type & Application
  5. 5.5 Global Idiopathic Pulmonary Fibrosis Disease Treatment Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Idiopathic Pulmonary Fibrosis Disease Treatment Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Idiopathic Pulmonary Fibrosis Disease Treatment Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Idiopathic Pulmonary Fibrosis Disease Treatment Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Blade Therapeutics
  2. 6.1.1 Blade Therapeutics Company Information
  3. 6.1.2 Blade Therapeutics Business Overview
  4. 6.1.3 Blade Therapeutics Idiopathic Pulmonary Fibrosis Disease Treatment Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Blade Therapeutics Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio
  6. 6.1.5 Blade Therapeutics Recent Developments
  7. 6.2 Bristol Myers Squibb
  8. 6.2.1 Bristol Myers Squibb Company Information
  9. 6.2.2 Bristol Myers Squibb Business Overview
  10. 6.2.3 Bristol Myers Squibb Idiopathic Pulmonary Fibrosis Disease Treatment Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Bristol Myers Squibb Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio
  12. 6.2.5 Bristol Myers Squibb Recent Developments
  13. 6.3 InterMune, Inc.
  14. 6.3.1 InterMune, Inc. Company Information
  15. 6.3.2 InterMune, Inc. Business Overview
  16. 6.3.3 InterMune, Inc. Idiopathic Pulmonary Fibrosis Disease Treatment Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 InterMune, Inc. Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio
  18. 6.3.5 InterMune, Inc. Recent Developments
  19. 6.4 Vicore Pharma
  20. 6.4.1 Vicore Pharma Company Information
  21. 6.4.2 Vicore Pharma Business Overview
  22. 6.4.3 Vicore Pharma Idiopathic Pulmonary Fibrosis Disease Treatment Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 Vicore Pharma Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio
  24. 6.4.5 Vicore Pharma Recent Developments
  25. 6.5 ArkBio
  26. 6.5.1 ArkBio Company Information
  27. 6.5.2 ArkBio Business Overview
  28. 6.5.3 ArkBio Idiopathic Pulmonary Fibrosis Disease Treatment Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 ArkBio Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio
  30. 6.5.5 ArkBio Recent Developments
  31. 6.6 Boehringer Ingelheim
  32. 6.6.1 Boehringer Ingelheim Company Information
  33. 6.6.2 Boehringer Ingelheim Business Overview
  34. 6.6.3 Boehringer Ingelheim Idiopathic Pulmonary Fibrosis Disease Treatment Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 Boehringer Ingelheim Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio
  36. 6.6.5 Boehringer Ingelheim Recent Developments
  37. 6.7 Regend Therapeutics (Cayman) Ltd.
  38. 6.7.1 Regend Therapeutics (Cayman) Ltd. Company Information
  39. 6.7.2 Regend Therapeutics (Cayman) Ltd. Business Overview
  40. 6.7.3 Regend Therapeutics (Cayman) Ltd. Idiopathic Pulmonary Fibrosis Disease Treatment Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 Regend Therapeutics (Cayman) Ltd. Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio
  42. 6.7.5 Regend Therapeutics (Cayman) Ltd. Recent Developments
  43. 6.8 Merck and Co., Inc.
  44. 6.8.1 Merck and Co., Inc. Company Information
  45. 6.8.2 Merck and Co., Inc. Business Overview
  46. 6.8.3 Merck and Co., Inc. Idiopathic Pulmonary Fibrosis Disease Treatment Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 Merck and Co., Inc. Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio
  48. 6.8.5 Merck and Co., Inc. Recent Developments
  49. 6.9 SHIONOGI & CO., Ltd.
  50. 6.9.1 SHIONOGI & CO., Ltd. Company Information
  51. 6.9.2 SHIONOGI & CO., Ltd. Business Overview
  52. 6.9.3 SHIONOGI & CO., Ltd. Idiopathic Pulmonary Fibrosis Disease Treatment Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 SHIONOGI & CO., Ltd. Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio
  54. 6.9.5 SHIONOGI & CO., Ltd. Recent Developments
  55. 6.10 Insilico Medicine
  56. 6.10.1 Insilico Medicine Company Information
  57. 6.10.2 Insilico Medicine Business Overview
  58. 6.10.3 Insilico Medicine Idiopathic Pulmonary Fibrosis Disease Treatment Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 Insilico Medicine Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio
  60. 6.10.5 Insilico Medicine Recent Developments
  61. 6.11 Indaco
  62. 6.11.1 Indaco Company Information
  63. 6.11.2 Indaco Business Overview
  64. 6.11.3 Indaco Idiopathic Pulmonary Fibrosis Disease Treatment Revenue, Global Share and Gross Margin (2021-2026)
  65. 6.11.4 Indaco Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio
  66. 6.11.5 Indaco Recent Developments
  67. 6.12 Zelgen
  68. 6.12.1 Zelgen Company Information
  69. 6.12.2 Zelgen Business Overview
  70. 6.12.3 Zelgen Idiopathic Pulmonary Fibrosis Disease Treatment Revenue, Global Share and Gross Margin (2021-2026)
  71. 6.12.4 Zelgen Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio
  72. 6.12.5 Zelgen Recent Developments
  73. 6.13 Heilongjiang Zbd Pharmaceutical
  74. 6.13.1 Heilongjiang Zbd Pharmaceutical Company Information
  75. 6.13.2 Heilongjiang Zbd Pharmaceutical Business Overview
  76. 6.13.3 Heilongjiang Zbd Pharmaceutical Idiopathic Pulmonary Fibrosis Disease Treatment Revenue, Global Share and Gross Margin (2021-2026)
  77. 6.13.4 Heilongjiang Zbd Pharmaceutical Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio
  78. 6.13.5 Heilongjiang Zbd Pharmaceutical Recent Developments
7 North America
  1. 7.1 North America Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Country (2021-2026)
  3. 7.3 North America Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Country (2021-2026)
  3. 8.3 Europe Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Country (2021-2026)
  3. 10.3 South America Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst